Portage Biotech Bolsters Pipeline With Acquisition Of Four Adenosine Pathway-Targeting Candidates

  • Portage Biotech Inc PRTG has agreed to acquire Tarus Therapeutics, a private company developing adenosine receptor antagonists.
  • Under the terms of the agreement, Portage will acquire Tarus for 2.4 million shares with the assumption of $3 million of liabilities. 
  • Additionally, payments of up to $32 million would be triggered upon achieving future development and sales milestones. 
  • As a result of the transaction, Portage acquires four assets, including:
  • TT-10 (now PORT-6): An adenosine receptor type 2A inhibitor for solid tumors. Portage expects to move into a Phase 1/2 trial by the end of 2022.
  • TT-4 (now PORT-7): An adenosine receptor type 2B inhibitor to treat solid tumors. Clinical development is expected to start in 2023.
  • TT-53 (now PORT-8): Dual inhibitor of adenosine receptors. Portage plans to submit an IND in the near future.
  • TT-3 (now PORT-9): Gut selective A2B inhibitor for gastrointestinal cancers, currently in preclinical studies.
  • Concurrent with the acquisition, Portage has entered into a committed share purchase agreement for up to $30 million with Lincoln Park Capital Fund LLC, extending Portage's total cash runway into 2024.
  • Price Action: PRTG shares closed higher by 2.52% at $7.72 on Wednesday.

Posted In: BriefsBiotechM&ANewsHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.